...
SPROMICRO

Spero Therapeutics, Inc.

HealthcareBiotechnology
$2.17
$0.00(-1.81%)
52W$0.51
$3.22
FinancialsValuationvs BNTX
Updated Mar 1, 12:00 AM
RSI40
RS Rating38/99
Beta0.86
Volatility63%
F-Score1/9
Mkt Cap$122M
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Spero Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 38), showing significant lag compared to the market leaders. Earnings growth of 59% provides fundamental context to the price action. Investors should exercise caution due to high volatility (63% annualized), which requires wider risk management.

Relative Strength
38
out of 99
Lagging
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
0.86
vs S&P 500
DEFENSIVE
52W Position
61%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$2.35
50 SMA > 100 SMA$2.35
100 SMA > 150 SMA$2.24
150 SMA > 200 SMA$2.27

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$2.29-5.38%BELOW
50 SMA$2.35-7.82%BELOW
100 SMA$2.35-7.66%BELOW
150 SMA$2.24-3.23%BELOW
200 SMA$2.27-4.26%BELOW

Price Performance

1D-1.8%
1W-3.1%
1M-2.7%
3M-9.6%
6M+8.5%
YTD-7.7%
1Y+179.8%
3Y+13.6%
52-Week Trading Range61% from low
$2.17
52W Low$0.51
52W High$3.22

Technical Indicators

RSI (14)NEUTRAL
40.1
305070
VCP ScoreCOOL
5/10
Base depth: 25.6%

Risk Profile

Beta
0.86
52W Vol
63%
ATR
$0.09
Max DD (1Y)
-40%

Volume Analysis

Today
2
50D Avg
236.6K
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24-141%
$-0.39
Q1'25-4%
$-0.25
Q2'25+91%
$-0.03
Q3'25+59%
$-0.13
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:+21.46%
3 Years:+150.01%
TTM:-64.72%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-12.43%

Stock Price CAGR

10 Years:-15.36%
5 Years:-35.07%
3 Years:+13.61%
1 Year:+179.78%

Return on Equity

10Y Avg:-146.6%
5Y Avg:-55.7%
3Y Avg:-40.4%
Last Year:-165.5%

Key Metrics

Market Cap$122M
Gross Margin-1.0%
Net Margin-1.4%
Piotroski F-Score1/9

More SPRO Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

SPRO vs BNTXBNTXMRNASMMTPCVX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 38 meansSPRO outperformed 38% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.86 means 14% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 1/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is SPRO in an uptrend right now?

SPRO has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is SPRO overbought or oversold?

SPRO's RSI (14) is 40. The stock is in neutral territory, neither overbought nor oversold.

Is SPRO outperforming the market?

SPRO has a Relative Strength (RS) Rating of 38 out of 99. SPRO is currently lagging the broader market.

Where is SPRO in its 52-week range?

SPRO is trading at $2.17, which is 67% of its 52-week high ($3.22) and 61% above its 52-week low ($0.51).

How volatile is SPRO?

SPRO has a Beta of 0.86 and 52-week volatility of 63%. It's less volatile than the S&P 500 - generally more stable.